Trimipramine Production Cost Reports

The report provides a detailed analysis essential for establishing a Trimipramine production plant. It encompasses all critical aspects necessary for Trimipramine production, including the cost of Trimipramine production, Trimipramine plant cost, Trimipramine production costs, and the overall Trimipramine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trimipramine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Trimipramine is a tricyclic antidepressant (TCA) that is used to treat major depressive disorder. It is utilised in endogenous and reactive forms, by stopping the reuptake of serotonin and norepinephrine in the brain to improve mood and alleviate symptoms like persistent sadness, fatigue, and anhedonia.

It shows sedative properties that make it suitable for depression accompanied by anxiety, agitation, insomnia, or sleep disturbances, as it enhances total sleep time and efficiency without suppressing REM sleep or causing rebound insomnia upon discontinuation. It is also utilised for nocturnal enuresis (bed-wetting) in children, neuropathic pain, obsessive-compulsive disorder, and as an adjunct in psychosis or delusional depression. Its common side effects include dry mouth, drowsiness, constipation, blurred vision, dizziness, nausea, weight gain, difficulty urinating, and orthostatic hypotension.

The market for Trimipramine is influenced by the growing cases of mental health disorders. Its utilisation in depression and anxiety, along with rising demand for sedative tricyclic antidepressants (TCAs) in cases with comorbid insomnia, agitation, or treatment-resistant depression, contributes to its market growth.

The rise in ageing populations increases the need for neuropathic pain or enuresis management, which fuels its demand. The expanding mental health awareness, healthcare infrastructure and hospital admissions for psychiatric conditions further boost its market. The industrial Trimipramine procurement is affected by its generic status with multiple API suppliers.  The price volatility influenced by raw material costs, GMP compliance, and regional negotiations impacts its sourcing. Also, other factors like competition from safer, less sedating alternatives like SSRIs and SNRIs, side effect profiles, etc. affects its market dynamics.

Raw Material for Trimipramine Production

According to the Trimipramine production plant project report, the key raw materials used in the production of Trimipramine include Bis(3-Dimethylamino-2-Methylpropyl)-5-Iminodibenzylyl Carboxylic acid and Ether.

Production Process of Trimipramine

The extensive Trimipramine production cost report consists of the following major industrial production process:

1. By Thermal Decarboxylation: The Trimipramine is manufactured through thermal decarboxylation of bis(3-dimethylamino-2-methylpropyl)-5-iminodibenzylyl carboxylic acid. This is heated at 185–250 degree Celsius until carbon dioxide evolution ceases, which forms a crude bis(3-dimethylamino-2-methyl-1-propyl)-5-iminodibenzyle product, which is dissolved in ether and washed with hydrochloric acid to separate impurities. The aqueous phase is then basified and re-extracted with ether, followed by drying and vacuum evaporation to get pure oil. This is finally converted to trimipramine maleate by treatment with maleic acid.

Trimipramine has the molecular formula of C20H26N2 (freebase, MW 294.4 g/mol) and formula C24H30N2O4. Its maleate salt has a molecular weight of 410.5 g/mol and appears as a white crystalline solid with a melting point of 140–144 degree Celsius. The maleate salt has limited water solubility but moderate lipophilicity with freebase LogP of 1.37–1.43. It has 6 rotatable bonds. It contains a seven-membered azepine ring fused to benzene rings with a dimethylamino-propyl side chain bearing a chiral centre. It goes through hepatic CYP2C19-mediated N-demethylation to active desmethyltrimipramine and CYP2D6-catalysed hydroxylation to inactive metabolites, exhibits 95%+ plasma protein binding, and 9–27 hour elimination half-life.